Notice NOT-DA-24-060 from the NIH Guide for Grants and Contracts

Notice NOT-TR-25-004 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-040 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-028 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this NOFO applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination.

Funding Opportunity PAR-25-155 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to enhance the capability of NCATS CTSA Program KL2 scholars and recipients of diversity and re-entry supplements supported by the CTSA Program to conduct research as they complete the transition to fully independent academic translational scientists. These R03 grants will support different clinical and translational science research projects, including pilot and feasibility studies; secondary data analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Research proposed in the R03 application may or may not include patient-oriented research. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide preliminary data to support submission of a subsequent R01, or equivalent, application.

Notice NOT-NS-25-007 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-154 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to solicit applications for pilot projects to identify new druggable targets for pain within the understudied druggable proteome. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s) listed in this NOFO. This NOFO is intended to jumpstart research on understudied proteins within the context of pain and pain management and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins to identify new druggable targets for pain. This NOFO is part of the NIH Helping to End Addiction Long Term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.

Funding Opportunity PAR-25-277 from the NIH Guide for Grants and Contracts. The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this NOFO is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community.This NOFO seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases within the mission of the NIDDK.

Funding Opportunity PAR-25-346 from the NIH Guide for Grants and Contracts. Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

Notice NOT-CA-25-020 from the NIH Guide for Grants and Contracts

Notice NOT-HD-24-045 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-030 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-029 from the NIH Guide for Grants and Contracts

Notice NOT-AG-24-074 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-029 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this NOFO applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This NOFO will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion NOFO that encourages applications for a collaborating Data Coordinating Center (PAR-22-193). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

Funding Opportunity RFA-AI-24-080 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support the development of improved products for treating Botulinum Neurotoxin (BoNT) intoxication. Development of products that can reverse BoNT intoxication are highly encouraged. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the R33 phase will depend on the successful completion of specific milestones during the R61 phase.

Funding Opportunity PAR-25-296 from the NIH Guide for Grants and Contracts. The CTSA Collaborative and Innovative Acceleration Award (CCIA) aims to accelerate the pace of translational research by supporting the collaborative development, dissemination, and sustainable implementation of innovative solutions across the CTSA Program Consortium and beyond. This Notice of Funding Opportunity (NOFO) invites investigator-initiated applications to develop, demonstrate, and disseminate innovative new approaches, technologies, resources, or models that increase the impact of research across diseases, transform the field of translational science, and bring more treatments for all people more quickly.

Funding Opportunity RFA-NR-25-003 from the NIH Guide for Grants and Contracts. The Transformative Research to Address Health Disparities and Advance Health Equity initiative is soliciting applications to support unusually innovative intervention research addressing social determinants of health (SDOH) which, if successful, would have a major impact on preventing, reducing, or eliminating health disparities and advancing health equity. Projects should clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact on advancing NIHs commitment to addressing SDOH to accelerate progress in improving health for all. Preliminary data are not required for this initiative.

Funding Opportunity PAR-25-321 from the NIH Guide for Grants and Contracts. Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

Notice NOT-OD-25-036 from the NIH Guide for Grants and Contracts